Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has received a consensus rating of “Moderate Buy” from the twenty-one brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seventeen have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $61.2632.

Several research analysts have recently commented on KYMR shares. HC Wainwright raised their price target on Kymera Therapeutics from $60.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. Jefferies Financial Group set a $64.00 target price on Kymera Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Saturday, September 27th. BTIG Research reiterated a “buy” rating and issued a $59.00 target price on shares of Kymera Therapeutics in a report on Thursday, June 26th. Finally, Wall Street Zen lowered Kymera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 16th.

Insiders Place Their Bets

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the sale, the chief executive officer directly owned 660,482 shares in the company, valued at $32,363,618. This trade represents a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Bruce N. Jacobs sold 79,220 shares of the firm’s stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.00, for a total value of $3,961,000.00. Following the completion of the sale, the chief financial officer owned 227,409 shares in the company, valued at approximately $11,370,450. This represents a 25.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 16.01% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Farther Finance Advisors LLC raised its stake in Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after buying an additional 540 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Kymera Therapeutics by 506.6% in the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after buying an additional 770 shares in the last quarter. Osaic Holdings Inc. raised its stake in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Kymera Therapeutics in the first quarter valued at $68,000. Finally, KBC Group NV raised its stake in Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company’s stock valued at $68,000 after buying an additional 328 shares in the last quarter.

Kymera Therapeutics Stock Down 0.6%

KYMR opened at $57.55 on Tuesday. Kymera Therapeutics has a 52 week low of $19.44 and a 52 week high of $59.00. The business has a fifty day simple moving average of $45.94 and a 200-day simple moving average of $39.60. The firm has a market cap of $4.11 billion, a P/E ratio of -16.58 and a beta of 2.26.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The firm had revenue of $11.48 million for the quarter, compared to analysts’ expectations of $17.37 million. During the same quarter in the prior year, the business earned ($0.58) earnings per share. The company’s quarterly revenue was down 55.1% on a year-over-year basis. Sell-side analysts expect that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.